COMBINATION OF AT LEAST TWO COMPOUNDS CHOSEN FROM GROUPS AT₁-RECEPTOR ANTAGONISTS OR INHIBITORS OF ACE (ANGIOTENSIN-CONVERTING ENZYME) OR INHIBITORS OF HMG-COA-REDUCTASE (BETA-HYDROXY-BETA-METHYLGLUTARYL-COENZYME-A-REDUCTASE)

摘要

FIELD: medicine, biochemistry, pharmacy.;SUBSTANCE: invention proposes using at least two therapeutic agents chosen from group of AT1-receptor antagonists comprising valsartan, losartan, candesartan, eprosartan, ipbesartan, saprisartan, tasosartan, telmisartan, E-1477, SC-52458, ZD-8731 and inhibitors of ACE (angiotensin-converting enzyme) chosen from group including alacepril, benazepril, benazeprilate, captopril, ceronapril, cilazapril, delapril, enalapril, enalaprilate, fosinopril, imidapril, lisinopril, moveltopril, perindopril, quinapril, ramipril, spirapril, temocapril and trandopril used in preparing a medicinal agent used in prophylaxis or treatment of endothelial dysfunction accompanying or not accompanying with hypertension, and the corresponding treatment method and a pharmaceutical composition. Synergistic effect of the mixture with respect to decreasing high blood pressure under condition of renal dysfunction is shown. The mixture enhanced viability of rats with endothelial dysfunction being without dependence of treatment resulting to blood pressure falling.;EFFECT: improved, enhanced and valuable properties of agents.;3 cl, 15 ex